Mineralys Therapeutics, Inc. MLYS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.03M+55.1% | $664K+3.3% | $643K-77.6% | $2.87M-73.1% | ||
| $0— | $0— | $0— | $0-100% | ||
| $32.75M+23.9% | $26.43M-28.9% | $37.18M+1,071% | $3.17M— | ||
| $661.39M+222% | $205.35M-17.6% | $249.1M+121% | $112.81M— | ||
| $38K-28.3% | $53K— | $0— | —— | ||
| $1.82M-7.7% | $1.98M-3.5% | $2.05M+659% | $270K— | ||
| $55.1M+254% | $15.58M+97.5% | $7.89M+37.5% | $5.74M— | ||
| $382K-23.4% | $499K+878% | $51K-96.9% | $1.63M— | ||
| $493.66M+333% | $113.92M-40.0% | $189.75M+747% | $22.41M— | ||
| $661.81M+221% | $205.9M-18.2% | $251.64M+120% | $114.44M— | ||
| $2.02M+321% | $479K-20.3% | $601K-68.5% | $1.91M— | ||
| $13.1M-7.6% | $14.17M+43.4% | $9.88M+60.4% | $6.16M— | ||
| $5.54M+54.7% | $3.58M+124% | $1.6M+140% | $665K— | ||
| $15.11M+3.2% | $14.65M+39.7% | $10.48M+29.9% | $8.07M— | ||
| 500M0.0% | 500M0.0% | 500M+56.7% | 319M— | ||
| $1.1B+124% | $493.77M+35.0% | $365.86M+67,651% | $540K— | ||
| -$457.17M-51.1% | -$302.52M-143% | -$124.71M-136% | -$52.81M— | ||
| $646.69M+238% | $191.26M-20.7% | $241.15M+561% | -$52.27M-128% | ||
| $661.81M+221% | $205.9M-18.2% | $251.64M+120% | $114.44M— | ||
| $3.22M+60.0% | $2.01M+135% | $857K+368% | $183K— | ||
| $21.6M+38.5% | $15.6M+174% | $5.7M— | —— | ||
| $493.84M+333% | $113.95M-40.0% | $189.78M+748% | $22.39M— | ||
| $59.5M+246% | $17.2M+100% | $8.6M+62.3% | $5.3M— | ||
| $656.6M+231% | $198.2M-17.1% | $239M— | —— | ||
| $382K-23.4% | $499K+878% | $51K-96.9% | $1.63M— | ||
| $382K-23.4% | $499K+878% | $51K-96.9% | $1.63M— | ||
| $121.25M+51.7% | $79.93M+154% | $31.5M+144% | $12.92M— | ||
| $13.1M-7.6% | $14.17M+43.4% | $9.88M+60.4% | $6.16M— | ||
| $13.1M-7.6% | $14.17M+43.4% | $9.88M+60.4% | $6.16M— | ||
| $4.1M+108% | $1.97M+69.9% | $1.16M+78.7% | $649K— | ||
| $6.49M+44.0% | $4.51M+319% | $1.08M+312% | $261K+121% | ||
| $0— | $0— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.00— | ||
| 81.5M+63.7% | 49.8M+21.1% | 41.1M+541% | 6.4M— | ||
| $146.32M+1,400% | $9.76M+17.7% | $8.29M-46.7% | $15.56M+14,720% | ||
| $8K+60.0% | $5K+25.0% | $4K+300% | $1K— | ||
| 2M+60.4% | 1.2M+163% | 464.9K— | —— | ||
| $32.3M+669% | $4.2M+31.3% | $3.2M— | $0— | ||
| 6.6M+44.2% | 4.6M+79.5% | 2.5M+86.0% | 1.4M+159% | ||
| $48.7M+79.0% | $27.2M+78.9% | $15.2M— | —— | ||
| 10.4M+24.1% | 8.4M+36.8% | 6.1M— | —— | ||
| $14.40+22.4% | $11.76+29.2% | $9.10+829% | $0.98+46.3% | ||
| $4.1M+108% | $1.97M+69.9% | $1.16M+78.7% | $649K— | ||
| $3.46M-59.8% | $8.61M+20.9% | $7.12M+47.0% | $4.85M— | ||
| $10.42M+24.1% | $8.4M+36.8% | $6.14M— | —— | ||
| $00.0% | $00.0% | $00.0% | $0— | ||
| $500M0.0% | $500M0.0% | $500M+56.7% | $319M— | ||
| $81.54M+63.7% | $49.82M+21.1% | $41.13M+541% | $6.42M— | ||
| $81.54M+63.7% | $49.82M+21.1% | $41.13M+541% | $6.42M— | ||
| $483.71M+475% | $84.1M-55.1% | $187.26M— | —— | ||
| $200K-50.0% | $400K— | $0-100% | $1.6M— | ||
| $39.94M-11.2% | $44.98M+199% | $15.04M+180% | $5.37M— | ||
| $1.82M-7.7% | $1.98M-3.5% | $2.05M+659% | $270K— | ||
| $121.25M+51.7% | $79.93M+154% | $31.5M+144% | $12.92M— | ||
| $0— | $0— | $0— | $0— | ||
| $55.1M+254% | $15.58M+97.5% | $7.89M+37.5% | $5.74M— | ||
| $244.6M+254% | $69M+97.1% | $35M+36.2% | $25.7M— | ||
| $59.5M+246% | $17.2M+100% | $8.6M+62.3% | $5.3M— | ||
| $21.17M+37.6% | $15.38M+171% | $5.67M+318% | $1.36M— | ||
| $121.25M+51.7% | $79.93M+154% | $31.5M+144% | $12.92M— | ||
| $48.7M+79.0% | $27.2M+78.9% | $15.2M— | —— | ||
| $1.96M+60.4% | $1.22M+163% | $464.93K— | —— | ||
| $6.58M+44.2% | $4.56M+79.5% | $2.54M+86.0% | $1.37M+159% | ||
| $32.3M+669% | $4.2M+31.3% | $3.2M— | $0— | ||
| $14.4+22.4% | $11.76+29.2% | $9.1+829% | $0.98+46.3% | ||
| $19.3M+117% | $8.9M+493% | $1.5M+1,400% | $100K— | ||
| $2.04M-18.7% | $2.51M-21.7% | $3.21M— | —— | ||
| $146.32M+1,400% | $9.76M+17.7% | $8.29M-46.7% | $15.56M+14,720% | ||
| $12.31+27.7% | $9.64+252% | $2.74— | —— | ||
| $46.98M+800% | $5.22M+67.6% | $3.11M— | —— | ||
| $6.49M+44.0% | $4.51M+319% | $1.08M+312% | $261K+121% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Mineralys Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 44.33 — current assets exceed current liabilities.
- Where does Mineralys Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.